SCHEMBL6320955

SCHEMBL6320955

CC(CS)NS(=O)(=O)c1ccc(I)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.53
CA1 P00915 6/20 0.53
ALDH1A1 P00352 5/20 0.49
CA9 Q16790 3/20 0.49
CA12 O43570 1/20 0.49
TSHR P16473 1/20 0.49
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
SIGMAR1 Q99720 3/20 0.43
CA7 P43166 1/20 0.41
POLB P06746 1/20 0.40
F2 P00734 1/20 0.40
PRSS1 P07477 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320961 1.00 CA2 (0.53) CA2CA1ALDH1A1CA9CA12
SCHEMBL6323466 0.84 CA2 (0.68) CA2CA1ALDH1A1CA9CA12
SCHEMBL6323465 0.84 CA2 (0.68) CA2CA1ALDH1A1CA9CA12
SCHEMBL6329758 0.83 CA2 (0.54) CA2CA1ALDH1A1CA9CA12
SCHEMBL6329763 0.83 CA2 (0.54) CA2CA1ALDH1A1CA9CA12
SCHEMBL6323690 0.83 CA2 (0.53) CA2CA1ALDH1A1CA9CA12
SCHEMBL6326224 0.83 NR3C1 (0.51) CA2CA1ALDH1A1CA9CA12
SCHEMBL6324072 0.83 MMP2 (0.53) CA2CA1ALDH1A1CA9CA12
SCHEMBL6323693 0.83 CA2 (0.53) CA2CA1ALDH1A1CA9CA12
SCHEMBL6326221 0.83 NR3C1 (0.51) CA2CA1ALDH1A1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CA2 492/4885CA1 196/4885ALDH1A1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.